早期子宫内膜样子宫内膜癌中半定量淋巴血管间隙浸润的分子亚组特异性预后价值
本研究回顾性纳入843例I-II期子宫内膜样子宫内膜癌患者,按分子分型评估三层淋巴血管间隙浸润(LVSI)的预后价值。中位随访70个月,MMRd组中局灶和大量LVSI均与无进展生存差相关,NSMP组仅大量LVSI有预后意义,p53abn组LVSI无预后意义,POLE超突变组因仅1例进展无法分析。
要点
- MMRd癌中局灶和大量LVSI均与无进展生存差相关(均P<0.001)。
- NSMP癌中仅大量LVSI有预后意义(P<0.001),局灶LVSI无(P=0.480)。
- p53abn癌中局灶(P=0.248)和大量(P=0.484)LVSI均无预后意义。
核心结论
- 在I-II期子宫内膜样子宫内膜癌中,三层LVSI的预后影响因分子亚组而异,凸显了按亚组进行风险评评估以改善个体化治疗决策和进展风险咨询的必要性。
研究设计与样本
- 回顾性研究,纳入单家三级中心治疗的I-II期子宫内膜样子宫内膜癌患者843例,中位随访70个月。
- 采用免疫组化和POLE测序进行分子分型,并测定雌激素受体和L1细胞黏附分子(L1CAM)表达。
主要发现
- 843例患者中,不同分子亚组间无进展生存和疾病特异性生存存在差异(P<0.001)。
- MMRd癌(n=364)中,局灶LVSI(P<0.001)和大量LVSI(P<0.001)均与无进展生存差相关。
- NSMP癌(n=359)中,仅大量LVSI有预后意义(P<0.001),局灶LVSI无预后意义(P=0.480)。
- p53abn癌(n=62)中,局灶LVSI(P=0.248)和大量LVSI(P=0.484)均无预后意义。
- 对分期(IA vs IB vs II)、分级(低级别vs高级别)、雌激素受体表达(三级量表)、L1CAM表达、年龄和辅助治疗进行双变量调整后,上述结果仍保持不变。
临床怎么用
- 原文未据此给出推荐。
局限性
- POLE超突变肿瘤(n=58)因仅1例进展而无法分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Molecular subgroups of endometrial carcinoma represent distinct disease entities, prompting subgroup-specific stratification. Recognizing lymphovascular space invasion (LVSI) as a key parameter in risk assessment, this study evaluates 3-tiered LVSI as a molecular subgroup-specific prognostic factor in stage I-II endometrioid endometrial cancer. METHODS: This retrospective study included patients treated at a single tertiary center. Immunohistochemistry and polymerase-ϵ (POLE) sequencing were conducted for molecular classification and determination of estrogen receptor and L1 cell adhesion molecule (L1CAM) expression. RESULTS: Among 843 eligible patients (median follow-up: 70 months), survival outcomes differed by molecular subgroup (P < 0.001 for progression-free survival and disease-specific survival). In MMRd carcinomas (n = 364), both focal (P < 0.001) and substantial (P < 0.001) LVSI were associated with poor progression-free survival. In NSMP carcinomas (n = 359), only substantial LVSI (P < 0.001) was prognostic (focal: P = 0.480). In p53abn carcinomas (n = 62), neither focal (P = 0.248) nor substantial (P = 0.484) LVSI showed prognostic significance. These findings remained after bivariate adjustments for stage (IA vs. IB vs. II), grade (low vs. high), estrogen receptor expression (3-tiered scale), L1CAM expression, age, and adjuvant therapy. Analysis was unfeasible for POLE ultramutated tumors (n = 58) due to a single progression. CONCLUSION: The prognostic impact of 3-tiered LVSI varied by molecular subgroup in stage I-II endometrioid endometrial cancer, highlighting the need for subgroup-specific risk assessment to improve individualized counceling on treatment decisions and risk of progression.
引用
- Loukovaara M, Pasanen A, Bützow R, et al. Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer. Gynecol Oncol. 2025. PMID: 40311527. doi:10.1016/j.ygyno.2025.04.589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。